293301-09-4

Upstream product

• 311819-99-5 3-(3,5-dimethoxyphenyl)-7-(tritylamino)-1,6-naphthyridin-2-ylformamide 
• 311820-00-5 3-(3,5-dimethoxyphenyl)-N⁷-trityl-1,6-naphthyridine-2,7-diamine 
• 311820-03-8 3-(3,5-dimethoxyphenyl)-N²,N²-bis(4-methoxybenzyl)-N⁷-trityl-1,6-naphthyridine-2,7-diamine 
• 13388-75-5 3,5-dimethoxyphenylacetonitrile 
• 179343-43-2 4,6-Diaminonicotinaldehyde 

Downstream Products

• 293301-35-6 3-(3,5-Dimethoxyphenyl)-7-{[3-(4-methylpiperazin-1-yl)propyl]amino}-1,6-naphthyridin-2-amine 
• 311820-03-8 3-(3,5-dimethoxyphenyl)-N²,N²-bis(4-methoxybenzyl)-N⁷-trityl-1,6-naphthyridine-2,7-diamine 
• 311820-04-9 3-(3,5-dimethoxyphenyl)-N²,N²-bis(4-methoxybenzyl)-1,6-naphthyridine-2,7-diamine 
• 311819-90-6 N-[2-[[(tert-butylamino)carbonyl]amino]-3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-7-yl]acetamide 
• 311819-88-2 1-[7-amino-3-(3,5-dimethoxy-phenyl)-[1,6]naphthyridin-2-yl]-3-tert-butyl-urea 
• 311819-96-2 3-(3,5-dimethoxyphenyl)-N²,N²,N⁷,N⁷-tetrakis(4-methoxybenzyl)-1,6-naphthyridine-2,7-diamine 
• 311820-00-5 3-(3,5-dimethoxyphenyl)-N⁷-trityl-1,6-naphthyridine-2,7-diamine 
• 311819-99-5 3-(3,5-dimethoxyphenyl)-7-(tritylamino)-1,6-naphthyridin-2-ylformamide 

Relevant academic research and scientific papers

3-(3,5-Dimethoxyphenyl)-1,6-naphthyridine-2,7-diamines and related 2-urea derivatives are potent and selective inhibitors of the FGF receptor-1 tyrosine kinase

A series of 3-aryl-1,6-naphthyridine-2,7-diamines and related 2-ureas were prepared and evaluated as inhibitors of the FGF receptor-1 tyrosine kinase. Condensation of 4,6-diaminonicotinaldehyde and substituted phenylacetonitriles gave intermediate naphthy

Synthesis of 7-substituted 3-aryl-l,6-naphthyridin-2-amines and 7-substituted 3-aryl-l,6-naphthyridin-2(1H)-ones via diazotization of 3-aryl-l ,6-naphthyridine-2,7-diamines

The preparation of 3-aryl-7-halo-l,6-naphthyridin-2-amines and 3-aryl-7-halo-l,6-naphthyridin-2(1H)-ones from the diazotization of 3-aryl-l,6-naphthyridine-2,7-diamines is reported. The reactions were investigated in various solvents (concentrated HC1, 50% HBF4, 70% HF-pyridine, 20% and 90% H2SO4, dilute HC;, and neat TFA). By appropriate choice of solvent and other conditions, good yields of the target compounds could be obtained, although in some cases a variety of different side products was also produced. Subsequent displacement of the 7-halogen substituents with alkylamines provides a route to more complex 7-substituted 1,6-naphthyridine derivatives that are potential tyrosine kinase inhibitors. The Royal Society of Chemistry 2000.